Company aTyr Pharma Inc Nasdaq
Equities
US0021201035
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 10 | 100.0 % | 0 | 100.0 % | -96.60% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 10 | 100.0 % | 0 | 100.0 % | -96.60% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 29/03/16 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 29/07/18 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 31/05/15 |
Ashlee Dunston
IRC | Investor Relations Contact | - | 31/03/20 |
Peter Villiger
PRN | Corporate Officer/Principal | - | 30/04/16 |
Human Resources Officer | - | 23/12/21 | |
General Counsel | - | 05/10/21 | |
Leslie Nangle
PRN | Corporate Officer/Principal | - | - |
Nancy Krueger
LAW | General Counsel | 56 | 30/09/14 |
Andrew B. Cubitt
PRN | Corporate Officer/Principal | - | 31/08/11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 07/09/05 |
Tim Coughlin
CHM | Chairman | 57 | 09/04/17 |
John Clarke
BRD | Director/Board Member | 70 | 31/08/05 |
Sara Zaknoen
BRD | Director/Board Member | 65 | 24/05/21 |
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 29/03/16 |
Jane Gross
BRD | Director/Board Member | 67 | 27/06/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 69,010,940 | 67,198,938 ( 97.37 %) | 0 | 97.37 % |
Company contact information
aTyr Pharma, Inc.
10240 Sorrento Valley Road Suite 300
92121, San Diego
+858 731 8389
http://www.atyrpharma.comSector
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |